Citigroup’s Liminatus Pharma LIMN Stock Holding History

Citigroup’s Portfolio LIMN Stock Details LIMN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.16K	Buy	6,769 +6,768	+676,800%	+$3.61K	﹤0.01%	5469
2025 Q4	$1	Buy	+1	New	+$1	﹤0.01%	6009

Other funds holding LIMN

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPIM

Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citigroup's LIMN Position: Q1 2026 in Review

Citigroup increased its Liminatus Pharma (LIMN) stake by 676,800% in Q1 2026, buying an estimated $3.61K and bringing the position to 6,769 shares worth $1.16K. The position accounts for ﹤0.01% of the portfolio, ranked #5469.

Citigroup first reported a position in LIMN in Q4 2025 and has held it in 2 quarters since. 15 funds tracked by Wall St. Rank hold LIMN as of Q1 2026.

Citigroup held 6,769 shares of Liminatus Pharma worth $1.16K as of Q1 2026.
Citigroup bought 6,768 Liminatus Pharma shares in Q1 2026, an estimated $3.61K.
Liminatus Pharma made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #5469 holding.
Citigroup first reported a position in Liminatus Pharma in Q4 2025 and has held it in 2 quarters since.
15 funds tracked by Wall St. Rank held Liminatus Pharma as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.